Lymphoma

Non-Hodgkin's Lymphoma

Criteria to qualify for study: Drug used in study:
  • —Hemoblobin A1C must be ≤ 6.4% 
  • Patient must  be tested for and be negative for HIV, Hep B & C 
  • PLT must be at least 75
  • ANC must be at least 1000
  • Creatinine ≤ 1.5 x ULN or Cr Cl ≥ 50 ml/min

SCRI  LYM 90

 A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Progressive Lymphoma

 

 

 

 

 

 

 

Criteria to qualify for study: Drug used in study:
  • —Roll over study for Hemref34 patients

Hemref 45 Infinity Pharmaceuticals INC Research

A Long-term, Continued Treatment and Follow-up Study in Subjects with Hematologic Malignancies Treate with Duvelisib (IPI-145)

 

 

 

 

 

 


Refractory/ Aggressive

Criteria to qualify for study: Drug used in study:
  • Must have stable disease or progressive disease as best response to most recent chemo or progresion within 12 months of prior auto transplant
  • Must have at least 1 measurable lesion
  • Must have MRI of the brain showing no evidence of CNS
  • No prior thereapy with a CD-19 target therapy

KTE-C19-101 Kite Pharma

A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Not Open

 

 

 

 

 

 

 

 

Criteria to qualify for study: Drug used in study:
  • Pathologically confirmed MCL with documentation of either overexpression of cyclin D1 or presence of t(11;14)
  • Up to 5 prior regimens for MCL and must include Anthracycline or Bendamustine containing chemo and Anti-CD20 monoclonal antibody therapy and Ibrutinib
  • ANC > 1000, Plt > 50 , serum creat < 1.5, bili < 1.5

LYM 111  KTE-C19-102 Kite Pharma

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19in subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Coming Soon

 

 

 

 

 

 

 

 

Criteria to qualify for study: Drug used in study:
  • Must have stable disease or progressive disease as best response to most recent chemo or progresion within 12 months of prior auto transplant
  • Must have at least 1 measurable lesion
  •  Must have MRI of the brain showing no evidence of CNS
  • No prior thereapy with a CD-19 target therapy         

LYM 100  SCRI Kite Pharma  KTE-C19-101

A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 (anti-CD19 CAR+ T) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL).     

 

 

 

 

 

 

 

Criteria to qualify for study: Drug used in study:
  • Phase IB - Patients must have histologically confirmed B-cell NHL (and have never received R-CHOP treatment), except MCL or SLL
  • Any relapsed/refractory patients who are enrolled during the dose excalation should have received only a single previous treatment regimen.         

LYM 104   SCRI   GO27878

A Phase IB/II, Open-Label Study Evaluating the Safety and Pharmacokinetics of GDC-0199 (ABT-199) in Combination with Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL     

 

 

 

 

 

 

 


Refractory/Indolent

Currently No Studies

 


Follicular/Untreated 

Criteria to qualify for study: Drug used in study:
  • Must be a Grade 1, 2, or 3a
    Must have histologically confirmed CD20
  • Ann-Arbor Stage 2 (non-contiguous), 3 or 4 disease 
  • Must have the presence of ≥1 lesion that measures ≥2.0 cm in the LD and ≥ 1.0 cm in the LPD as assessed by CT or MRI
  • Cannot have known history of transformed lymphoma or diffuse large cell lymphoid malignancy
  • Cannot be a candidate for stem cell transplantation or potentially curative radiotherapy

LYM 99 Gilead    GS-US-313-1414

A Phase 2, Single Arm Study Evaluating the Safety and Efficacy of Idelalisib in Combination with Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma  

 

 

 

 

 

 

 

 

 

 

Criteria to qualify for study: Drug used in study:
  • ECOG Performance Status of 0-2
  • Life expectancy of at least 12 weeks
  • History of histologically documented relapsed or refractory Grades 1-3a follicular lymphoma or relapsed or refractory diffuse large B-cell lymphoma
  • Must have at least one bi-dimensionally measurable lesion > 1.5 cm in its largest dimension by CT scan or MRI.

LYM 82

A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of Pinatuzumab Vedotin (DCDT2980S) in Combination with Rituximab or Polatuzumab Vedotin (DCDS4501A) in Combination with Rituximab and a Non-Randomized Phase Ib/II Evaluation of Polatuzumab Vedotin in Combination With Obinutuzumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

 

 

 

 

 

 

 

 

 

 


Relapsed/Refractory

Criteria to qualify for study: Drug used in study:
  • Phase 1a Escalation
  • Advanced lymphoma after failure of at least 2 prior regimens with at least 1 site of measurable disease (> 1.5 cm in long axis or > 1.0 cm in both long and short axis
  • ANC > 1.5 / PLT > 75 HGB > 10 in absence of transfusion and growth factors for at least 28 days /ECOG 0,1 or 2

Hemref 43   Trillium           

A Phase 1a/1b Dose Escalation and Expansion Trial of Single agen TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relpased of Refractory Hematologic Malignancies   

 

 

 

 

 

 

 

 

Criteria to qualify for study: Drug used in study:
  • Must have previously received at least 2 prior systemic regimens with a CD20 target therapy, an alkylatnig agent, an anthracycline, or a steroid
  • Cannot be eligible for transplant
  • Cannot have primary mediastinal (thymic) large B-cell lymphoma or CNS involvement 
  • Cannot have prolonged QTc interval

LYM 101 SCRI  ProNAi           

A Phase II Study of PNT2258 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.  WOLVERINE  

ON HOLD 

 

 

 

 

 

 

 

 

Criteria to qualify for study: Drug used in study:
  • —Availability of an archival or freshly biopsied tumor tissue sample must be confirmed for study enrollment
  • ANC ≥ 1000
  • PLT ≥ 75
  • HGB ≥ 9
  • Serum Creatinine ≤ 2 or creatinine clearance ≥ 50
  • Prior allo trasnplant is excluded
  • Auto transplant not allowed before Day 100
  • Patients eligible for auto transplant are excluded

LYM 82 SCRI Genentech GO27834           

A Non-Randomized, Phase IB/II Evaluation of Polatuzumab Vedotin (DCDS4501A) in Combination with Obinutuzumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. ROMULUS   

 

 

 

 

 

 

 

 

 

Criteria to qualify for study: Drug used in study:
  • Patient cannot have Richter's syndromes
  • Patient cannot have undergone prior allogeneic stem cell transplant
  • Patient cannot be receiving a strong CYP3A4 inhibitor or inducer or a proton pum inhibitor (PPI) or Acid Reducing Agent (ARA)

HEMREF 35 SCRI Portola PRT062070              

A Phase I Open-Label, Multi-Dose, Dose Escalation Study of PRT062070 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell Non-Hodgkin Lymphoma (NHL)   

ON HOLD

 

 

 

 

 

 

 

 


Relapsed Refractory for Phase II  Untreated for Phase IB

 

Currently No Studies


 

Hodgkin's Lymphoma

 

Criteria to qualify for study: Drug used in study:
  • —Hemoblobin A1C must be ≤ 6.4% 
  • Patient must  be tested for and be negative for HIV, Hep B & C 
  • PLT must be at least 75
  • ANC must be at least 1000
  • Creatinine ≤ 1.5 x ULN or Cr Cl ≥ 50 ml/min

SCRI  LYM 90

 A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Progressive Lymphoma

 

 

 

 

 

 


Relapsed/Refractory

 

Criteria to qualify for study: Drug used in study:
  • Phase 1a Escalation
  •  Advanced lymphoma after failure of at least 2 prior regimens with at least 1 site of measurable disease (> 1.5 cm in long axis or > 1.0 cm in both long and short axis
  • ANC > 1.5 / PLT > 75
  • HGB > 10 in absence of transfusion and growth factors for at least 28 days /
  • ECOG 0,1 or 2

Hemref 43 Trillium

A Phase 1a/1b Dose Escalation and Expansion Trial of Single agen TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relpased of Refractory Hematologic Malignancies